Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Strengthened Clinical and Regulatory Leadership Team with Key AppointmentsStart-up Activities for the Global Phase 3 Trial Ongoing with Release of Drug Product Manufactured with Commercial Process and First Patient Expected to be Dosed in 2H 2023BOSTON (BUSINESS WIRE) Aura Biosciences Inc. (NASDAQ: AURA), a clinic.
Published: Jul 02, 2021 By Alex Keown
OcuTerra Therapeutics – David J. Tanzer was named Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs for Boston-based OcuTerra. Prior to joining OcuTerra, Tanzer served as Global Executive Medical Director in the Novartis ophthalmology franchise. Before that, he served as the CMO at Abbott Medical Optics. He also led the Navy Refractive Surgery Program in San Diego, participating as principal or co-investigator in over 50 clinical studies.
Delix Therapeutics – David E. Olson, co-founder and Chief Scientific Officer of Delix Therapeutics, was an Innovator of the Year award winner at UC Davis. Olson is an assistant professor in the Department of Chemistry and Department of Biochemistry and Molecular Medicine at UC Davis. He was named an Innovator of the Year for his groundbreaking work with non-hallucinatory psychedelics that have the potential to make “measurable societal impact.” Olson and his